Igor Vivanco, PhD, King’s College London, London, UK, comments on novel developments in the treatment landscape for glioblastoma. The current standard of care for BRAF-mutant gliomas, which constitute a small number of total patients with glioma, is BRAF and MEK inhibitors. As drug resistance can occur when using targeted therapies, there is a need to elucidate strategies to overcome resistance. Immunotherapies such as checkpoint inhibitors has additionally been assessed in glioblastoma and may show promise as a debulking regimen in conjunction with existing therapies. This interview took place at the British Neuro-Oncology Society (BNOS) Annual Meeting 2022.